share_log

NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share

Financial News Live ·  Jan 26, 2023 09:13

NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report issued on Monday, January 23rd. William Blair analyst M. Phipps forecasts that the company will earn ($0.16) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.

Get NewAmsterdam Pharma alerts:

NAMS has been the subject of a number of other research reports. SVB Leerink began coverage on NewAmsterdam Pharma in a report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price target for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a report on Monday, December 19th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Credit Suisse Group initiated coverage on NewAmsterdam Pharma in a research report on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price on the stock.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS opened at $11.30 on Thursday. NewAmsterdam Pharma has a fifty-two week low of $7.52 and a fifty-two week high of $32.88. The business has a 50 day moving average of $10.29.

NewAmsterdam Pharma Company Profile

(Get Rating)

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.

Read More

  • Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
  • Mergers and Acquisitions in 2023 Off To A Strong Start
  • What Does Apple's Move to India Mean for Investors?
  • AMD Is Still One Of The Best Semiconductor Stocks Out There
  • Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
  • Is The Bottom In For Cyber-Security Stocks?

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment